尽管 COVID-19 收入下降且年度展望被修正，但 Moderna 在 2025 年第三季度凭借强劲的呼吸道疫苗销售超出了盈利预期。 Moderna beat earnings estimates in Q3 2025 with strong respiratory vaccine sales, despite lower COVID-19 revenue and a revised annual outlook.

Moderna 报告称，尽管 COVID-19 疫苗收入同比下降 45%，但受呼吸道疫苗销售强劲推动的 2025 年第三季度财务业绩好于预期，收入为 10.2 亿美元，每股净亏损为 0.51 美元。 Moderna reported a better-than-expected third-quarter 2025 financial performance with $1.02 billion in revenue and a net loss of $0.51 per share, driven by strong respiratory vaccine sales despite a 45% year-over-year decline in COVID-19 vaccine revenue. 该公司将其全年收入前景降至16亿至20亿美元,理由是政府需求减少,美国新的指导方针限制获得最新照片的机会。 The company lowered its full-year revenue outlook to $1.6–2.0 billion, citing reduced government demand and new U.S. guidelines limiting access to updated shots. 通过提高效率和确定方案优先次序,将现代业务开支削减34%,以66亿美元现金结束本季度。 Moderna cut operating expenses by 34% through efficiency gains and program prioritization, ending the quarter with $6.6 billion in cash. 它获得了40个国家最新COVID-19和RSV疫苗的核准,推进了流感和流感COVID混合疫苗候选方案,并报告了肿瘤治疗早期积极数据,同时中止了CMV疫苗方案。 It secured approvals for its updated COVID-19 and RSV vaccines in 40 countries, advanced its flu and flu-COVID combination vaccine candidates, and reported early positive data for an oncology therapy, while discontinuing a CMV vaccine program.